Bio-Path Holdings operates as a clinical and preclinical stage oncology focused antisense drug development company. The Company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. It has a number of drug candidates for the treatment of acute myeloid leukemia, chronic myelogenous leukemia, solid tumors and lymphoma.

Type
Public
HQ
Bellaire, US
Founded
2007
Size (employees)
12 (est)
Bio-Path Holdings was founded in 2007 and is headquartered in Bellaire, US
Report incorrect company information

Bio-Path Holdings Office Locations

Bio-Path Holdings has an office in Bellaire
Bellaire, US (HQ)
4710 Bellaire Blvd Suite 210
Show all (1)
Report incorrect company information

Bio-Path Holdings Financials and Metrics

Bio-Path Holdings Financials

Bio-Path Holdings's revenue was reported to be $13 k in FY, 2016
USD

Net income (Q1, 2018)

(1.9 m)

Market capitalization (23-May-2018)

19.7 m

Closing share price (23-May-2018)

1.7

Cash (31-Mar-2018)

4.3 m
Bio-Path Holdings's current market capitalization is $19.7 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

13 k

EBIT

(15.7 m)(4.5 m)(5.5 m)(8.5 m)

EBIT margin, %

(65192%)

Interest income

4 k22.6 k17.7 k12 k
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Revenue

General and administrative expense

786.4 k566.6 k519.9 k849 k757 k681 k970 k845 k987 k

R&D expense

107.6 k517 k424.5 k592.5 k564.4 k992.4 k1 m1.2 m2.3 m1 m1.5 m932 k

Operating expense total

510.2 k1.3 m1.2 m1.4 m1.1 m1.5 m1.9 m1.9 m3 m2 m2.3 m1.9 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

3.6 m13.9 m8.9 m9.4 m

Current Assets

3.7 m14.1 m9.6 m10.7 m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Cash

16.8 m15.7 m14.6 m12.5 m11.1 m9.9 m6.5 m4.2 m11.3 m7.1 m6.2 m4.3 m

Current Assets

17.2 m16 m14.9 m12.9 m12 m10.5 m7.8 m6.1 m12.4 m8.4 m7.8 m5.9 m

PP&E

102.8 k92.6 k82.3 k62 k51 k66 k872 k797 k605 k

Total Assets

18.6 m17.4 m16.3 m14.2 m13.3 m11.7 m8.9 m7.1 m13.4 m10.1 m9.4 m7.2 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(3.3 m)(4.5 m)(5.5 m)(6.8 m)

Depreciation and Amortization

10.3 k41.1 k43 k

Accounts Payable

(34.3 k)267.1 k375.4 k(146 k)
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Net Income

(504.9 k)(1.8 m)(2.9 m)(1.4 m)(2.5 m)(4 m)(1.9 m)(3.8 m)(5.4 m)(397 k)(2.4 m)(1.9 m)

Depreciation and Amortization

10.3 k20.6 k30.9 k10 k21 k31 k33 k108 k106 k

Accounts Payable

125.1 k38.6 k(11.7 k)54.3 k130.2 k(80.7 k)(37 k)(124 k)(71 k)(208 k)(257 k)138 k

Cash From Operating Activities

(544.4 k)(1.6 m)(2.7 m)(1.4 m)(2.8 m)(4 m)(2.4 m)(4.6 m)(6.5 m)(1.8 m)(4.2 m)(1.7 m)
USDY, 2018

Financial Leverage

1.1 x
Show all financial metrics
Report incorrect company information